A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruiting · Phase 3 · NCT06859268

Conditions: Obesity

Research payments reported, 2025: $13.4M
U.S. investigators named: 30
Sites paid: 26
Planned or actual enrollment: 643

About the trial

Sponsor: Eli Lilly and Company
Tested: Retatrutide (drug), Placebo (drug)
Dates: Started 2025-03-05; completion 2028-04
Results posted: Not yet

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

From ClinicalTrials.gov, last updated 2026-03-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $13.4M in research payments for this study in 2025 (30 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it